TRC 4186
Alternative Names: TRC-4186; TX-41XXLatest Information Update: 15 Apr 2021
Price :
$50 *
At a glance
- Originator Torrent Pharmaceuticals
- Class Heart failure therapies; Hydrazines; Pyridinium compounds; Small molecules; Sulfones; Thiophenes
- Mechanism of Action Advanced glycosylation end product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic complications; Heart failure
Most Recent Events
- 15 Apr 2021 TRC 4186 is still in phase II trials for Diabetic complications and Heart failure
- 15 Apr 2021 Torrent Pharmaceuticals plans a phase III trial for Heart failure (Adjunctive treatment) in 2020
- 23 Feb 2018 TRC 4186 is still in phase II trials for Diabetic complications and Heart failure (Torrent Pharma pipeline, February 2018)